Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis allows generic sales in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties.

The agreement settles a three-year US patent infringement suit issued against generic manufacturers Barr Pharmaceuticals and Teva Pharmaceuticals. The agreement states that in exchange for royalties, Barr and Teva can sell cheaper versions of the allergy drugs Allegra and Nasacort in the US. Royalties are to be applied to sales retrospectively.

Under the terms of the agreement, Barr will have an option to purchase the finished pharmaceutical product from sanofi-aventis on a non-exclusive basis.

Sanofi-aventis is continuing with ongoing patent infringements suits against other generic manufacturers.

In 2007, US sales of Allegra and Nasacort totalled $276m and $301m, respectively.

19th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics